Pharmacies risk violating civil rights laws if they deny access to drugs that can be used for abortion, HHS says

Pharmacies risk violating civil rights laws if they deny access to drugs that can be used for abortion, HHS says


Shoppers wait in line at the pharmacy of a Walmart store in Charlotte, North Carolina.

Callaghan O’Hare | Bloomberg | Getty Images

The Health and Human Services Department on Wednesday warned U.S. retail pharmacies that they risk violating civil rights law if they deny access to medication used in abortions under certain circumstances.

The HHS Office for Civil Rights said pharmacies cannot deny access to prescription medication used for reproductive health-care on the basis of the customer’s sex, pregnancy status and other protected groups under federal civil rights law.

This may include the prescription of the abortion pill, mifepristone used in combination with misoprostol, to assist with first-trimester miscarriages. The medication can also be used to terminate an unwanted pregnancy, according to HHS guidance issued to the nation’s 60,000 retail pharmacies.

HHS also said pharmacies risk violating civil rights law if they refuse to fill a prescription for methotrexate to halt ectopic pregnancies.

People who believe a pharmacy is discriminating against them can file a complaint with the HHS Office of Civil rights, an official at the department told reporters on a call Wednesday. Complaints will be reviewed on a case by case basis, the official said.

“The Department is committed to improving maternal health — including for individuals who experience miscarriages — and vigorous enforcement of our civil rights laws is one way in which we plan to do so,” HHS said in guidance issued to the nation’s 60,000 retail pharmacies.

The Affordable Care Act prohibits recipients of federal financial assistance from discriminating on the basis of sex, race, color, national origin, age and disability. Federal civil rights law prohibits discrimination on the basis of current, past or intended pregnancy as well as medical conditions related to pregnancy, according to HHS.

Medication used to terminate pregnancies has become a flashpoint between the Biden administration and states who are banning abortion in the wake of the Supreme Court overturning Roe v. Wade last month, which protected the procedure as a constitutional right for nearly 50 years.

The FDA approved mifepristone more than 20 years ago as a safe and effective way to end a pregnancy before 10 weeks. In December, the FDA said it would permanently allow women to receive the pill by mail from licensed health-care providers.

But states that have banned abortion in the wake of the Supreme Court’s ruling have also outlawed the administration of drugs that terminate pregnancies. The abortion bans generally make exceptions for the procedure when the women’s life is in danger.

This is a developing story. Please check back for updates.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 
Health

Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 

The Omada Health logo is displayed on a smartphone screen. Sopa Images | Lightrocket | Getty Images Virtual care company Omada Health on Thursday said it will start prescribing GLP-1s and other obesity drugs and helping patients manage those medications. Omada plans to expand the offerings under its weight management program as its membership grows […]

Read More
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
Health

Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage

U.S. President Donald Trump attends an event to make an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming […]

Read More
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 
Health

Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 

Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli Lilly on Thursday said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, called eloralintide, helped patients […]

Read More